The Challenges Ahead With Monoclonal Antibodies-Reference-Cited by-同舟云学术

The Challenges Ahead With Monoclonal Antibodies

Published:2020-12-01 Issue:21 Volume:324 Page:2151
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Goldstein Robert H.¹²,Walensky Rochelle P.³²

Affiliation:

1. Division of Infectious Diseases and Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston

2. Harvard Medical School, Boston, Massachusetts

3. Division of Infectious Diseases, Massachusetts General Hospital, Boston

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2773057/jama_goldstein_2020_vp_200232_1606767676.32945.pdf

Reference10 articles.

1. GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial.;Spinner;JAMA,2020

2. Emergency Use Authorization of remdesivir: the need for a transparent distribution process.;Ison;JAMA,2020

3. Missed opportunities on emergency remdesivir use.;Sarpatwari;JAMA,2020

4. Regeneron’s REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients. News release. Regeneron; September 29, 2020. Accessed October 17, 2020. https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and

5. Woolf? SH, Chapman? DA, Sabo? RT, Weinberger? DM, Hill? L, Taylor? DDH. Excess deaths from COVID-19 and other causes, March-July 2020. JAMA. Published online October 12, 2020.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. REGULATORY CHALLENGES AND LANDSCAPES OF MONOCLONAL ANTIBODY REGISTRATION: GLOBAL OUTLOOK;International Journal of Pharmacy and Pharmaceutical Sciences;2024-05-01

2. Underuse of SARS-CoV-2–Neutralizing Monoclonal Antibodies in Skilled Nursing Facilities;Journal of the American Medical Directors Association;2024-02

3. Treatment patterns and factors associated with discontinuation of monoclonal antibodies;SAGE Open Medicine;2024-01

4. Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial;Open Forum Infectious Diseases;2023-07-14

5. Real-World Implementation of a COVID-19 Monoclonal Antibody Treatment Program in a Los Angeles County Safety Net Ambulatory Healthcare System — Barriers to Treatment and Lessons Learned;Journal of Racial and Ethnic Health Disparities;2023-07-05